Boston Scientific Corp. lowered its 2026 financial outlook following an August cyberattack that disrupted global operations alongside a downturn in its cardiovascular business. The company expects full-year adjusted EPS of $3.16 to $3.18 and annual net sales growth of about 4.25%, down from prior guidance. Fourth-quarter sales are projected to fall up to 3%. Chief Financial Officer Jon Monson cited a turned growth cycle and announced a new operating model to improve future forecasting.
August cyberattack on operations
- ▪Boston Scientific Corp. suffered a cyberattack in August 2026 that interrupted its global operations
- ▪Shortly after an August 2026 cyberattack, Boston Scientific disclosed that it would not meet its initial full-year targets for net sales or adjusted earnings
2026 financial performance decline
- ▪Boston Scientific shares declined 4.6% to $43 in premarket trading on October 28, 2026
- ▪Boston Scientific stock fell 9% on the morning of October 28, 2026, after losing 53% year-to-date through October 27, 2026
Lowered earnings outlook
- ▪Boston Scientific reduced its expected 2026 annual net sales growth forecast to approximately 4.25%, down from its previous guidance of 5.5% to 6.5%
- ▪Boston Scientific lowered its full-year 2026 adjusted earnings per share projection to $3.16–$3.18, down from $3.28–$3.32 and below Wall Street consensus estimates of $3.23
Story comments
Loading comments…